Market research
ADPT Adaptive Biotechnologies Corp
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 30.2143
- Dividend yield
- Not available
- Beta
- 2.1
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- Not available
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 30.2143
- Dividend yield
- Not available
- Beta
- 2.1
About
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Research context
Adaptive Biotechnologies Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ADPT discussion.
5 years, 6 months ago
Adaptive Biotechnologies Corporation is currently in a long term downtrend where the price is trading 18.5% below its 200 day moving average.
From a valuation standpoint, the stock is 95.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 54.8.
Adaptive Biotechnologies Corporation's total revenue rose by 24.7% to $30M since the same quarter in the previous year.
Its net income has dropped by 116.2% to $-45M since the same quarter in the previous year.
Finally, its free cash flow fell by 68.5% to $-49M since the same quarter in the previous year.
Based on the above factors, Adaptive Biotechnologies Corporation gets an overall score of 2/5.